Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935918 | 1.00 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL1781384 | 1.00 | — | — | |
| SCHEMBL8003633 | 0.96 | HIF1A (0.46) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Hydrochloric Acid SCHEMBL7744897 | 0.96 | HIF1A (0.46) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Bromide SCHEMBL7745419 | 0.96 | HIF1A (0.46) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Thiomorpholine SCHEMBL93637 | 0.96 | HIF1A (0.42) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Thiomorpholine SCHEMBL145846 | 0.96 | — | — | |
| Thiomorpholine SCHEMBL2273 | 0.96 | — | — | |
| SCHEMBL9873225 | 0.96 | HIF1A (0.42) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL1615244 | 0.92 | HIF1A (0.39) | HIF1AMAPTPDE4AKDRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4739230-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | claimed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | claimed |
| JP-2007514745-A | — | — | 2007-06-07 | — | — | JP | claimed |
| US-20060287291-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-21 | — | — | US | claimed |
| EP-1694663-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | Biovitrum Aktiebolag (SE) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058858-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | BIOVITRUM AB (SE) | 2005-06-30 | — | — | WO | claimed |
| US-5192781-A | Cardiovascular | LABORATOIRES UPSA (FR) | 1993-03-09 | — | — | US | claimed |
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20060287291-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1694663-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | Biovitrum Aktiebolag (SE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058858-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | BIOVITRUM AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1149094-B1 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-6376491-B1 | BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS | BASILEA PHARMACEUTICA AG (CH) | 2002-04-23 | — | — | US | disclosed |
| EP-1149094-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287291-A1 | Compounds | HTR6, HTR1B, HTR1A | HIF1A 1912/4885MAPT 1414/4885PDE4A 957/4885 |
| US-20110015185-A1 | Benzofuran Compounds | HTR6, HTR1F, HTR1A | HIF1A 1767/4885MAPT 2205/4885PDE4A 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.